FrancophonIA/ELRC3.0 huggingface dataset:
English: Injection button
Croatian: Indukcijska doza
English: Idacio therapy should not be continued in patients failing to respond within this time period.
Croatian: U bolesnika u kojih u ovom razdoblju ne bude odgovora, liječenje lijekom Idacio ne treba nastaviti.
English: • The needle guard spring is not extended (Figure I).
Croatian: opruga štitnika igle nije ispružena (slika I).
English: subcutaneous dose was 64%.
Croatian: koncentracije su bile proporcionalne dozi.
English: • You might get infections more easily while you are receiving Idacio treatment.
Croatian: • Dok primate lijek Idacio, možete biti podložniji infekcijama.
English: STATEMENT OF ACTIVE SUBSTANCE(S) One 0.8 mL pre-filled syringe contains 40 mg adalimumab
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna napunjena brizgalica od 0,8 ml sadrži 40 mg adalimumaba.
English: Idacio 40 mg solution for injection in pre-filled pen adalimumab
Croatian: Idacio 40 mg otopina za injekciju u napunjenoj brizgalici adalimumab
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1356/001
Croatian: BROJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/19/1356/001
English: Sodium dihydrogen phosphate dihydrate Disodium phosphate dihydrate Mannitol
Croatian: Drugi sastojci su: natrijev dihidrogenfosfat dihidrat, natrijev hidrogenfosfat dihidrat, manitol,
English: If you take Idacio the risk of getting lymphoma, leukaemia, or other cancers may increase.
Croatian: Rizik obolijevanja od limfoma, leukemije ili drugih tumora može se povećati ako primjenjujete lijek Idacio.
English: Pancreatitis,
Croatian: • svrbež,
English: 0.8 mL solution in pre-filled PhysiojectTM pen containing a pre-filled syringe (type I glass) with a 29G
Croatian: Idacio 40 mg otopina za injekciju u napunjenoj brizgalici 0,8 ml otopine u napunjenoj brizgalici (PhysiojectTM ) koja sadrži napunjenu štrcaljku (staklo tipa I) s iglom (29G Thin-Wall, ½ inča) s poklopcem za iglu bez lateksa i sa čepom klipa (sintetička guma).
English: STATEMENT OF ACTIVE SUBSTANCE(S) One 0.8 mL vial contains 40 mg adalimumab
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna bočica od 0,8 ml sadrži 40 mg adalimumaba.
English: • adolescent hidradenitis suppurativa
Croatian: • gnojnog hidradenitisa u adolescenata
English: Idacio dose for paediatric patients with plaque psoriasis Patient weight
Croatian: Tablica 5. Doza lijeka Idacio za pedijatrijske bolesnike s uveitisom Tjelesna težina bolesnika
English: There is no relevant use of Idacio in children aged less than 2 years in this indication.
Croatian: Nema relevantne primjene adalimumaba u djece mlađe od 2 godine u ovoj indikaciji.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1356/002
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/19/1356/002
English: opportunistic infections and tuberculosis (including coccidioidomycosis, histoplasmosis and mycobacterium avium complex infection), bacterial infections,
Croatian: često sistemske infekcije (uključujući sepsu, kandidijazu i gripu), intestinalne infekcije (uključujući virusni gastroenteritis), infekcije kože i mekog tkiva (uključujući paronihiju,
English: Adult hidradenitis suppurativa
Croatian: Adolescentni gnojni hidradenitis
English: Beyond 16 weeks, patients with inadequate response to Idacio 40 mg every other week may benefit from an increase in dosage to 40 mg every week or 80 mg every other week.
Croatian: U bolesnika u kojih nije postignut zadovoljavajući odgovor na Idacio u dozi od 40 mg svaki drugi tjedan nakon 16 tjedana, možda će biti korisno povećati doziranje na 40 mg lijeka svaki tjedan ili 80 mg svaki drugi tjedan.
English: Aortic aneurysm, vascular arterial occlusion, thrombophlebitis
Croatian: Krvožilni poremećaji često hipertenzija, navale crvenila, hematomi manje često aneurizma aorte, okluzije arterijskih žila, tromboflebitis
English: Adalimumab 40 mg weekly
Croatian: Adalimumab/ MTX 40 mg svaka dva tjedna
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.8 mL
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA
English: If your child takes Idacio the risk of getting lymphoma, leukaemia, or other cancers may increase.
Croatian: Rizik obolijevanja od limfoma, leukemije ili drugih tumora može se povećati ako Vaše dijete primjenjuje lijek Idacio.
English: 5.1 Wipe the skin of your injection site with an alcohol pad to clean it. (Figure M) Warning: Do not blow on or touch the injection site after cleaning.
Croatian: 5.1 Da biste očistili mjesto injiciranja, kožu prebrišite jastučićem natopljenim alkoholom (slika M).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1356/003
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/19/1356/003
English: Table 17 Ps Study I (REVEAL) efficacy results at 16 weeks Placebo N=398 n (%)
Croatian: Tablica 17 Ispitivanje Ps I (REVEAL) Rezultati djelotvornosti nakon 16 tjedana
English: kg
Croatian: Klip
English: Adverse reaction dysphagia, face oedema
Croatian: • edem (oticanje) lica,
English: Room spinning sensation (vertigo) and vision disturbances may occur after taking Idacio.
Croatian: Nakon uzimanja lijeka Idacio može se javiti osjećaj da se prostorija vrti (vrtoglavica) te smetnje vida.
English: Your healthcare provider should show you how to prepare and inject Idacio properly using the vial kit before you use it for the first time.
Croatian: Prije nego što primijenite ovaj lijek prvi puta, Vaš zdravstveni radnik Vam mora pokazati kako se Idacio ispravno priprema i primjenjuje koristeći set s bočicom.
English: Back view
Croatian: Straga
English: Table 10 Radiographic mean changes at week 52 in RA study V MTX n=257 confidence interval)
Croatian: Tablica 10 Srednje vrijednosti promjena radioloških nalaza nakon 52 tjedna u ispitivanju RA V
English: Leucopaenia (including neutropaenia and agranulocytosis), anaemia
Croatian: vrlo često leukopenija (uključujući neutropeniju i agranulocitozu), anemija često leukocitoza, trombocitopenija manje često idiopatska trombocitopenična purpura
English: Note: P = Placebo (number at risk (flared)); A = Adalimumab (number at risk (flared)).
Croatian: Napomena: P = Placebo (Broj bolesnika pod rizikom [bolesnici s egzacerbacijom]); A = Adalimumab (Broj bolesnika pod rizikom [bolesnici s egzacerbacijom]).
English: Table 26 Paediatric CD study PCDAI clinical remission and response
Croatian: Indukcija kliničke remisije i kliničkog odgovora
English: The joint survey drug utilisation final study report submitted by the MAHs, together with the joint database drug utilisation final study report submitted by the MAHs as a separate procedure (EMEA/H/N/PSR/J/0003), complies with their obligation to conduct a drug utilisation study to characterise prescribing practices for the medicinal product during typical and clinical use in representative groups of prescribers and to assess the main reason for prescription as imposed during the Article 107i procedure EMA/H/A-107i/1357 for cyproterone/ethinylestradiol containing products.
Croatian: Završno izvješće ispitivanja potrošnje lijekova na temelju zajedničkog pregleda koje su podnijeli nositelji odobrenja za stavljanje lijeka u promet, uz završno izvješće ispitivanja potrošnje lijekova na temelju zajedničke baze podataka koje su podnijeli nositelji odobrenja za stavljanje lijeka u promet u zasebnom postupku (EMEA/H/N/PSR/J/0003), u skladu je s njihovom obvezom provođenja ispitivanja potrošnje lijekova kako bi se opisale prakse propisivanja lijeka u uobičajenoj i kliničkoj upotrebi u reprezentativnoj skupini liječnika koji propisuju lijek te radi procjene glavnih razloga propisivanja kako je zadano tijekom postupka EMA/H/A-107i/1357 po članku 107i za lijekove koji sadrže ciproteron/etinilestradiol.
English: Therefore, in view of available data regarding the joint survey drug utilisation final study report, together with the joint database drug utilisation final study report submitted as a separate procedure (EMEA/H/N/PSR/J/0003), the PRAC considered that changes to the conditions of the marketing authorisation were warranted.
Croatian: Stoga, s obzirom na dostupne podatke o završnom izvješću o ispitivanju potrošnje lijekova na temelju zajedničkog pregleda, uz završno izvješće ispitivanja potrošnje lijekova na temelju zajedničke baze podataka podnesenog u zasebnom postupku (EMEA/H/N/PSR/J/0003), PRAC smatra da su izmjene uvjeta odobrenja za stavljanje lijeka u promet opravdane.
English: • This medicine must not be mixed with other infusion solutions.
Croatian: • Ovaj lijek se ne smije miješati s drugim infuzijskim otopinama.
English: • Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.
Croatian: • Uvijek primijenite ovaj lijek točno onako kako je opisano u ovoj uputi ili kako Vam je rekao Vaš liječnik ili ljekarnik.
English: Determine the point of injection and prepare antiseptically 14.
Croatian: Odredite mjesto injiciranja i pripremite ga antiseptički.
English: Filtering can be achieved by following the reconstitution and/or administration steps as described below.
Croatian: Filtriranje se može postići tako da se slijede koraci za pripremu i/ili primjenu kako je opisano niže.
English: Warm both unopened vial and syringe in your hands to a comfortable temperature (do not exceed 37 °C).
Croatian: Neotvorenu bočicu i štrcaljku ugrijte rukama do ugodne temperature (ne više od 37 °C).
English: Mean baseline clearance for 14 adult patients undergoing major surgeries with continuous infusion are 188 ml/h corresponding to 3.0 ml/h/kg (range 1.6-4.6 ml/h/kg).
Croatian: Srednji ishodni klirens 14 odraslih bolesnika podvrgnutih opsežnim kirurškim zahvatima uz kontinuiranu infuziju iznosio je 188 ml/h, što odgovara 3,0 ml/h/kg (raspon od 1,6 do 4,6 ml/h/kg).
English: In extensive post-registration observational studies with KOGENATE Bayer, involving more than 1000 patients the following was observed: Less than 0.2% PTP developed de-novo inhibitors.
Croatian: U opsežnim opservacijskim ispitivanjima lijeka KOGENATE Bayer nakon registracije koja su obuhvaćala više od 1000 bolesnika zabilježeni su sljedeći rezultati: u manje od 0,2% prethodno liječenih bolesnika razvili su se de-novo inhibitori.
English: Then, strongly press down the fingerplate near the syringe tip using your thumb and index finger (C) until the finger plate meets the top edge of the Bio-Set.
Croatian: Zatim palcem i kažiprstom čvrsto pritisnite graničnike za prste blizu vrha štrcaljke prema dolje (C) dok se ne spoje s gornjim rubom uređaja Bio-Set.
English: • This medicine is intended for intravenous administration only and should be administered within 3 hours after reconstitution.
Croatian: • Ovaj lijek namijenjen je isključivo za primjenu u venu te se mora primijeniti u roku od 3 sata nakon pripreme za primjenu.
English: In one observational study, the incidence of inhibitor development in previously untreated patients with severe haemophilia A was 64/183 (37.7%) with KOGENATE Bayer (followed up to 75 exposure days).
Croatian: U jednom opservacijskom ispitivanju, incidencija razvoja inhibitora u prethodno neliječenih bolesnika s teškom hemofilijom A bila je 64/183 (37,7%) uz KOGENATE Bayer (praćenih do 75 dana izloženosti).
English: Remove protective cap from the vial (A) then clean the rubber stopper with a sterile swab (or use an antiseptic spray).
Croatian: Uklonite zaštitni čep s bočice (A) te očistite gumeni čep sterilnom blazinicom (ili antiseptičkim sprejem).
English: The safety and efficacy of KOGENATE Bayer in children of all ages have been established.
Croatian: Pedijatrijska populacija Sigurnost i djelotvornost lijeka KOGENATE Bayer ustanovljena je u djece svih dobi.
English: The pre-filled syringe contains water for injections to be used to reconstitute the contents of the vial.
Croatian: Napunjena štrcaljka sadrži vodu za injekciju koja služi za pripremu za primjenu sadržaja bočice.
English: In clinical studies, KOGENATE Bayer has been used in the treatment of bleeding episodes in 37 previously untreated patients (PUPs) and 23 minimally treated paediatric patients (MTPs, defined as having ≤4 exposure days) with residual FVIII:C < 2 IU/dl.
Croatian: U kliničkim ispitivanjima, KOGENATE Bayer se upotrebljavao za liječenje krvarenja u 37 prethodno neliječenih bolesnika (PNB) te 23 minimalno liječena pedijatrijska bolesnika (MLB, definirani kao izloženi lijeku ≤4 dana) s rezidualnim FVIII C < 2 IU/dl.
English: The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Croatian: LIJEKA Plan upravljanja rizicima (RMP) Nositelj odobrenja obavljat će dodatne farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom, a koji je opisan u Modulu 1.8.2.
English: Additional pharmacokinetic parameters for KOGENATE Bayer for bolus injection are: mean residence time [MRT (0-48)] of about 22 hours and clearance of about 160 ml/h.
Croatian: Dodatni su farmakokinetički parametri lijeka KOGENATE Bayer prilikom ubrizgavanja bolusa sljedeći: prosječno vrijeme zadržavanja [MRT (0-48)] od oko 22 sata te klirens od oko 160 ml/h.
English: It is recommended that every time that you use KOGENATE Bayer, the name and batch number of the product are documented.
Croatian: Dokumentiranje Preporučuje se da se svaki put kad primijenite KOGENATE Bayer zabilježe naziv i broj serije lijeka.
English: If you cannot use the venipuncture set provided, use a separate filter which is compatible with KOGENATE Bayer.
Croatian: Ako ne možete uporabiti priloženi komplet za venepunkciju, uporabite zasebni filter koji je kompatibilan s lijekom KOGENATE Bayer.
English: Filtering is achieved by using the vial adapter.
Croatian: Filtriranje se postiže pomoću uporabe nastavka za bočicu.
English: KOGENATE Bayer should be injected intravenously over several minutes.
Croatian: KOGENATE Bayer injicira se intravenski tijekom nekoliko minuta.
English: If a package is opened or damaged, do not use this medical device.
Croatian: Ako je pakiranje otvoreno ili oštećeno, nemojte koristiti taj medicinski proizvod.
English: The vial contains a dry white to slightly yellow powder or cake.
Croatian: Bočica sadrži suhi bijeli do žućkasti prašak ili kolačić.
English: If you have any questions about KOGENATE Bayer and compatible separate filters contact your doctor.
Croatian: Ako imate dodatnih pitanja o lijeku KOGENATE Bayer i kompatibilnim zasebnim filterima, obratite se svom liječniku.
English: Data show that KOGENATE Bayer has been used to induce immune tolerance.
Croatian: KOGENATE Bayer primjenjivao za izazivanje imunološke tolerancije.
English: • If for the administration of KOGENATE Bayer you will require a central venous access device (CVAD), the risk of CVAD-related complications including local infections, bacteria in the blood (bacteremia) and the formation of a blood clot in the blood vessel (thrombosis) where the catheter is inserted should be considered by your doctor.
Croatian: • Ako Vam je zbog primjene lijeka KOGENATE Bayer potrebno postaviti centralni venski kateter, Vaš liječnik treba uzeti u obzir rizik od komplikacija povezanih s centralnim venskim kateterom, kao što su lokalne infekcije, bakterije u krvi (bakterijemija) i stvaranje krvnog ugruška u krvnoj žili (tromboza) u koju je uveden kateter.
English: If you have any questions about KOGENATE Bayer and compatible separate filters contact Bayer Pharma AG.
Croatian: Ako imate dodatnih pitanja o lijeku KOGENATE Bayer i kompatibilnim zasebnim filterima, obratite se tvrtki BayerPharma AG.
English: Reconstitute the desired amount of product, repeating steps 2.
Croatian: Pripremite željenu količinu lijeka prema postupku iz koraka od 2 do 9.
English: • Do not use the venipuncture set provided for drawing blood because it contains an in-line filter.
Croatian: • Nemojte uporabiti priloženi komplet za venepunkciju za uzimanje krvi, zato što sadrži ugrađeni filter.
English: • You must use aseptic conditions (meaning clean and germ free) during reconstitution and administration.
Croatian: • Tijekom pripreme i primjene moraju se koristiti aseptički uvjeti (što znači da okruženje mora biti čisto i bez mikroorganizma).
English: When you must withdraw blood before an infusion, use an administration set without a filter, then infuse KOGENATE Bayer through an injection filter.
Croatian: Kada prije infuzije morate uzeti krv, uporabite komplet za primjenu bez filtera, a potom primijenite KOGENATE Bayer infuzijom kroz injekcijski filter.
English: If you notice any of the following symptoms during injection/infusion:
Croatian: Ako tijekom ubrizgavanja/infuzije primijetite bilo koji od sljedećih simptoma: • stezanje u prsima/ osjećaj opće slabosti
English: • If you experience tightness in the chest, feeling dizzy, feeling sick or faint, or experience dizziness on standing, you may be experiencing a rare severe sudden allergic reaction (a socalled anaphylactic reaction) to this medicine.
Croatian: • Ako osjetite stezanje u prsima, omaglicu, mučninu ili nesvjesticu, ili pak omaglicu prilikom ustajanja jer to mogu biti znakovi rijetke, ali teške i iznenadne alergijske reakcije (takozvane anafilaktičke reakcije) na ovaj lijek.
English: Finally, apply a small pressure dressing to the wound.
Croatian: Na kraju lagano stisnite ranu zavojem.
English: Hold the pre-filled sterile water for injection (SWFI) syringe upright, grasp the plunger rod per the diagram and attach the rod by turning it firmly clockwise into the threaded stopper (C).
Croatian: Napunjenu štrcaljku sa sterilnom vodom za injekciju držite uspravno, a zatim uzmite potisni klip kao što je prikazano na slici te ga čvrsto zakrećite u smjeru kretanja kazaljke na satu u graničnik s navojima (C).
English: The analysis of all recorded in vivo recoveries in previously treated patients demonstrated a mean rise of 2 % per IU/kg body weight for KOGENATE Bayer.
Croatian: Analiza svih oporavaka in vivo zabilježenih u prethodno liječenih bolesnika pokazala je da prilikom korištenja lijeka KOGENATE Bayer dolazi do srednje vrijednosti porasta razine faktora od 2% po
English: It is strongly recommended that every time that KOGENATE Bayer is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.
Croatian: Dokumentiranje Snažno se preporučuje da se pri svakoj primjeni lijeka KOGENATE Bayer zabilježi naziv i serijski broj lijeka kako bi se održala veza između bolesnika i serije lijeka.
English: Detailed instructions for preparation and administration are contained in the package leaflet provided with KOGENATE Bayer.
Croatian: Detaljne upute za pripremu i primjenu lijeka navedene su u Uputi o lijeku koja se isporučuje uz KOGENATE Bayer.
English: It has been shown in a clinical study performed with adult haemophilia A patients who undergo a major surgery that KOGENATE Bayer can be used for continuous infusion in surgeries (pre-, during and postoperative).
Croatian: Kliničko ispitivanje provedenu u odraslih bolesnika s hemofilijom A u kojih se radi veliki kirurški zahvat pokazalo je da se KOGENATE Bayer može koristiti za kontinuiranu infuziju kod operacije
English: MARKETING AUTHORISATION HOLDER Bayer Pharma AG 13342 Berlin Germany
Croatian: Nositelj odobrenja za stavljanje gotovog lijeka u promet Bayer Pharma AG 13342 Berlin Njemačka
English: Holding the plunger in place, remove the syringe from the vial adapter (the latter should remain attached to the vial).
Croatian: Klip pridržavajte na mjestu, a štrcaljku odvojite od nastavka za bočicu (nastavak mora ostati pričvršćen za bočicu).
English: Other medicines and KOGENATE Bayer 3000 IU Interactions with other medicines are not known.
Croatian: Drugi lijekovi i KOGENATE Bayer 3000 IU Nisu poznate interakcije s drugim lijekovima.
English: If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for the presence of factor VIII inhibitor should be performed.
Croatian: Ako se ne postignu očekivane razine aktivnosti faktora VIII u plazmi ili ako se krvarenje ne može kontrolirati odgovarajućom dozom, potrebno je provesti pretragu na prisutnost inhibitora faktora VIII.
English: If you use more KOGENATE Bayer 250 IU than you should No cases of overdose with recombinant coagulation factor VIII have been reported.
Croatian: Ako primijenite više lijeka KOGENATE Bayer 250 IU nego što ste trebali Nije zabilježen niti jedan slučaj predoziranja rekombinantnim koagulacijskim faktorom VIII.
English: Only the provided components (powder vial with Bio-Set device, pre-filled syringe containing solvent and venipuncture set) should be used for reconstitution and injection because treatment failure can occur as a consequence of human recombinant coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.
Croatian: Za pripremu za primjenu i injiciranje smiju se koristiti samo priložene komponente (bočica praška s uređajem Bio-Set, napunjena štrcaljka koja sadrži otapalo i set za venepunkciju) jer zbog adsorpcije ljudskog rekombinantnog koagulacijskog faktora VIII u unutrašnje površine određene infuzijske opreme liječenje može biti neuspješno.
English: This result is similar to the reported values for factor VIII derived from human plasma.
Croatian: Bayer slični su vrijednostima postignutima primjenom faktora VIII dobivenog iz plazme.
English: • You must filter the reconstituted product before administration to remove potential particulate matter in the solution.
Croatian: • Pripremljeni lijek prije primjene morate filtrirati kako biste iz otopine uklonili moguće čestice.
English: If the inhibitor is present at levels less than 10 Bethesda Units (BU) per ml, administration of additional recombinant coagulation factor VIII may neutralise the inhibitor and permit continued clinically effective therapy with KOGENATE Bayer.
Croatian: Ako je prisutna razina inhibitora manja od 10 Bethesda jedinica (BU) po ml, dodatna primjena rekombinantnog koagulacijskog faktora VIII
English: What KOGENATE Bayer 500 IU is and what it is used for What you need to know before you use KOGENATE Bayer 500 IU How to use KOGENATE Bayer 500 IU Possible side effects
Croatian: Što je KOGENATE Bayer 500 IU i za što se koristi Što morate znati prije nego što počnete primjenjivati KOGENATE Bayer 500 IU
English: What KOGENATE Bayer 250 IU is and what it is used for
Croatian: Što je KOGENATE Bayer 250 IU i za što se koristi
English: Use only the medical devices (vial adapter, pre-filled syringe containing solvent and venipuncture set) for reconstitution and administration that are provided with each package of this medicine.
Croatian: Za pripremu i primjenu koristite samo medicinske proizvode (nastavak za bočicu, štrcaljku napunjenu otapalom i set za venepunkciju) koji su priloženi u svakom pakiranju ovog lijeka.
English: INFORMATION IN BRAILLE KOGENATE Bayer 2000
Croatian: 16. PODACI NA BRAILLEOVOM PISMU KOGENATE Bayer 2000
English: Five out of 37 (14%) PUP and 4 out of 23 (17%) MTP patients treated with KOGENATE Bayer developed inhibitors within 20 exposure days.
Croatian: Inhibitori su se razvili unutar 20 dana izloženosti u 5 od 37 (14%) prethodno neliječenih bolesnika te u 4 od 23 (17%) minimalno liječena pedijatrijska bolesnika koji su primali KOGENATE Bayer.
English: What KOGENATE Bayer 250 IU contains
Croatian: Što KOGENATE Bayer 250 IU sadrži
English: Do not use KOGENATE Bayer 250 IU
Croatian: Nemojte primjenjivati KOGENATE Bayer 250 IU
English: If you forget to use KOGENATE Bayer 250 IU
Croatian: Ako ste zaboravili primijeniti KOGENATE Bayer 250 IU
English: INFORMATION IN BRAILLE KOGENATE Bayer 250
Croatian: 16. PODACI NA BRAILLEOVOM PISMU KOGENATE Bayer 250
English: Do not use KOGENATE Bayer 500 IU
Croatian: Nemojte primjenjivati KOGENATE Bayer 500 IU
English: - 9, using a new syringe and connect it to the venipuncture set.
Croatian: Za to koristite novu štrcaljku te je priključite na komplet za venepunkciju.
English: Do not use KOGENATE Bayer 2000 IU
Croatian: Nemojte primjenjivati KOGENATE Bayer 2000 IU
English: Do not use KOGENATE Bayer 3000 IU
Croatian: Nemojte primjenjivati KOGENATE Bayer 3000 IU
English: What KOGENATE Bayer 2000 IU contains
Croatian: Što KOGENATE Bayer 2000 IU sadrži